Literature DB >> 7069409

Appearance of complement components and immunoglobulins on nasopharyngeal epithelial cells following naturally acquired infection with respiratory syncytial virus.

T N Kaul, R C Welliver, P L Ogra.   

Abstract

Nasopharyngeal epithelial cells (NPEC) were collected from 144 infants and children with respiratory syncytial virus (RSV) infection, and were analyzed by fluorescent antibody techniques for the presence of cell-bound complement (C'3), IgA, IgG, and IgM class of immunoglobulins (Ig), and respiratory syncytial virus antigen. Viral antigen was present on the surface of NPEC in 100% of samples obtained in the first 3 days or illness. The percentage of patients positive for RSV antigen declined steadily, so that no patient still expressed viral antigen on NPEC by 57 days after the onset of illness. Cell-bound IgA, IgG, and IgM could be detected in most of the samples tested in the first 13 days after the onset of illness. Subsequently, the frequency of detection of cell-bound Ig gradually declined. Only 8-33% of patients tested 57 days after the onset of illness expressed IgA, IgG, or IgM on NPEC. About 45% of samples tested in the first 8 weeks after the onset of illness exhibited complement binding to NPEC. The percentage of subjects showing cell-bound C'3 reached a maximum at 8-13 says after the onset of illness, while cell-bound C'3 could not be detected in any of the samples collected 57-90 days after the onset of illness. Although cell-bound C'3 was generally present in association with cell-bound Ig on NPEC, in a small percentage (4.6%) of patients cell-bound C'3 could be detected in the absence of any cell-bound Ig. Cell-bound C'3 and IgA, IgG, and IgM were present with equal frequency in patients with all forms of clinical disease caused by RSV, and in patients less than or greater than 6 months of age at the onset of illness.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7069409      PMCID: PMC7166695          DOI: 10.1002/jmv.1890090210

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  20 in total

1.  Activation of the alternative pathway of guinea pig complement by Sendai virus-treated cells.

Authors:  N Okada; H Shibuta; H Okada
Journal:  Microbiol Immunol       Date:  1979       Impact factor: 1.955

2.  Antibody-independent neutralization of vesicular stomatitis virus by human complement. I. Complement requirements.

Authors:  B J Mills; N R Cooper
Journal:  J Immunol       Date:  1978-10       Impact factor: 5.422

3.  The coating of respiratory syncytial (RS) virus-infected cells in the respiratory tract by immunoglobulins.

Authors:  P S Gardner; J McQuillin
Journal:  J Med Virol       Date:  1978       Impact factor: 2.327

4.  Influence of immunological factors in respiratory syncytial virus disease.

Authors:  R M Chanock; A Z Kapikian; J Mills; H W Kim; R H Parrott
Journal:  Arch Environ Health       Date:  1970-09

5.  Cell-free and cell-bound antibody in nasal secretions from infants with respiratory syncytial virus infection.

Authors:  K McIntosh; J McQuillin; P S Gardner
Journal:  Infect Immun       Date:  1979-02       Impact factor: 3.441

6.  Secretory antibody response to respiratory syncytial virus infection.

Authors:  T N Kaul; R C Welliver; D T Wong; R A Udwadia; K Riddlesberger; P L Ogra
Journal:  Am J Dis Child       Date:  1981-11

7.  The role of complement in viral infections. III. Activation of the classical and alternative complement pathways by Sindbis virus.

Authors:  R L Hirsch; J A Winkelstein; D E Griffin
Journal:  J Immunol       Date:  1980-05       Impact factor: 5.422

8.  The immunologic response to infection with respiratory syncytial virus in infants.

Authors:  K McIntosh; H B Masters; I Orr; R K Chao; R M Barkin
Journal:  J Infect Dis       Date:  1978-07       Impact factor: 5.226

9.  Comparison of fluorescent-antibody, neutralizing-antibody, and complement-enhanced neutralizing-antibody assays for detection of serum antibody to respiratory syncytial virus.

Authors:  T N Kaul; R C Welliver; P L Ogra
Journal:  J Clin Microbiol       Date:  1981-05       Impact factor: 5.948

10.  Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway.

Authors:  N R Cooper; F C Jensen; R M Welsh; M B Oldstone
Journal:  J Exp Med       Date:  1976-10-01       Impact factor: 14.307

View more
  14 in total

Review 1.  The respiratory syncitial virus and its role in acute bronchiolitis.

Authors:  M L Everard; A D Milner
Journal:  Eur J Pediatr       Date:  1992-09       Impact factor: 3.183

Review 2.  Immunity to human and bovine respiratory syncytial virus.

Authors:  T G Kimman; F Westenbrink
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

Review 3.  Respiratory syncytial virus. Brief review.

Authors:  E J Stott; G Taylor
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

Review 4.  Correlates of Protection Against Respiratory Syncytial Virus Infection in Infancy.

Authors:  Bahaa Abu-Raya; Frederic Reicherz; Pascal M Lavoie
Journal:  Clin Rev Allergy Immunol       Date:  2022-06-11       Impact factor: 8.667

5.  Interaction of polymorphonuclear leukocytes and viruses in humans: adherence of polymorphonuclear leukocytes to respiratory syncytial virus-infected cells.

Authors:  H Faden; J J Hong; P L Ogra
Journal:  J Virol       Date:  1984-10       Impact factor: 5.103

6.  Virus-induced complement activation and neutrophil-mediated cytotoxicity against respiratory syncytial virus (RSV).

Authors:  T N Kaul; H Faden; R Baker; P L Ogra
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

7.  Complement activation by respiratory syncytial virus-infected cells.

Authors:  K M Edwards; P N Snyder; P F Wright
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

Review 8.  The Human Immune Response to Respiratory Syncytial Virus Infection.

Authors:  Clark D Russell; Stefan A Unger; Marc Walton; Jürgen Schwarze
Journal:  Clin Microbiol Rev       Date:  2017-04       Impact factor: 26.132

9.  Neisseria cinerea Expresses a Functional Factor H Binding Protein Which Is Recognized by Immune Responses Elicited by Meningococcal Vaccines.

Authors:  Hayley Lavender; Katy Poncin; Christoph M Tang
Journal:  Infect Immun       Date:  2017-09-20       Impact factor: 3.441

Review 10.  Innate Immune Components that Regulate the Pathogenesis and Resolution of hRSV and hMPV Infections.

Authors:  Catalina A Andrade; Gaspar A Pacheco; Nicolas M S Gálvez; Jorge A Soto; Susan M Bueno; Alexis M Kalergis
Journal:  Viruses       Date:  2020-06-12       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.